Form4insider filings, from the source

SEC Form 4 · accession 0001209191-16-096129

Evoke Pharma Inc · EVOK

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Matthew J D'Onofrio
Officer — Exec VP, Chief Bus. Officer
Period of report
Feb 5, 2016
Accepted (ET)
Feb 5, 2016 · 7:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F2,F1$8.67Feb 5, 2016D94,250D—Dec 1, 2023Common Stock94,2500D
Stock Option (Right to Buy)F4,F3$6.22Feb 5, 2016D70,000D—Mar 5, 2025Common Stock70,0000D
Stock Option (Right to Buy)F5$3.04Feb 5, 2016A70,687A—Dec 1, 2023Common Stock70,68770,687D
Stock Option (Right to Buy)F5$3.04Feb 5, 2016A52,500A—Mar 5, 2025Common Stock52,50052,500D

Explanation of responses